Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
出版年份 2020 全文链接
标题
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
作者
关键词
-
出版物
Alzheimers Research & Therapy
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-08-12
DOI
10.1186/s13195-020-00663-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
- (2020) Shorena Janelidze et al. NATURE MEDICINE
- Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
- (2020) Thomas K Karikari et al. LANCET NEUROLOGY
- Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
- (2019) Niklas Mattsson et al. JAMA Neurology
- A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease
- (2019) Ebrima Gibbs et al. Scientific Reports
- Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease
- (2019) Bernard J. Hanseeuw et al. JAMA Neurology
- Modulation of Amyloid-β42 Conformation by Small Molecules Through Nonspecific Binding
- (2019) Chungwen Liang et al. Journal of Chemical Theory and Computation
- The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
- (2019) Martin Tolar et al. Alzheimers & Dementia
- A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers
- (2019) Agnès Portron et al. CLINICAL THERAPEUTICS
- Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
- (2019) Kaj Blennow et al. Scientific Reports
- Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
- (2019) Gregory Klein et al. Alzheimers Research & Therapy
- Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer’s disease brain
- (2018) Wei Hong et al. ACTA NEUROPATHOLOGICA
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
- (2018) John A. Hey et al. CNS DRUGS
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- (2018) Bernd Bohrmann et al. JOURNAL OF ALZHEIMERS DISEASE
- Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
- (2018) Philip Scheltens et al. Alzheimers Research & Therapy
- Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders
- (2018) Bob Olsson et al. JAMA Neurology
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases
- (2016) Tina Bilousova et al. AMERICAN JOURNAL OF PATHOLOGY
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
- (2016) Jinping Wang et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate
- (2016) Ting Yang et al. JOURNAL OF NEUROSCIENCE
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
- (2016) Veronika Logovinsky et al. Alzheimers Research & Therapy
- The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
- (2016) Urmi Sengupta et al. EBioMedicine
- Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
- (2015) Kirsten L. Viola et al. ACTA NEUROPATHOLOGICA
- Amyloid Oligomers Disrupt Blood-CSF Barrier Integrity by Activating Matrix Metalloproteinases
- (2015) M. Brkic et al. JOURNAL OF NEUROSCIENCE
- Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease
- (2014) Dietmar Rudolf Thal et al. ACTA NEUROPATHOLOGICA
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity
- (2014) Nicholas J. Izzo et al. PLoS One
- Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls
- (2012) Thomas J. Esparza et al. ANNALS OF NEUROLOGY
- Soluble A Promotes Wild-Type Tau Pathology In Vivo
- (2012) M. A. Chabrier et al. JOURNAL OF NEUROSCIENCE
- Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid Peptide
- (2012) T. Hashimoto et al. JOURNAL OF NEUROSCIENCE
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Oligomers of β-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model
- (2009) Renee C. Gaspar et al. EXPERIMENTAL NEUROLOGY
- Effect of tramiprosate in patients with mild-to-moderate alzheimer’s disease: Exploratory analyses of the MRI sub-group of the alphase study
- (2009) S. Gauthier et al. Journal of Nutrition Health & Aging
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started